Traditional MedicarePrior AuthHigh impact
Epoetin Alfa (Epogen, Procrit, Retacrit) (Revised)
Humana·SC, VA · Nephrology, Oncology, Hematology +5 more·Medicaid
Effective date
Jan 1, 2025
We identified it
Jul 22, 2026
Summary
Humana has revised its Epoetin Alfa (Epogen, Procrit, Retacrit) prior authorization policy effective January 1, 2025, establishing unified clinical criteria across Medicare and Medicaid (South Carolina and Virginia) for seven anemia indications. The policy requires prior authorization for all three products, specifies preferred vs. non-preferred product hierarchies with step-therapy requirements, and mandates documentation of hemoglobin levels, iron stores, and exclusion of other anemia causes before approval.
Action Required
By January 1, 2025: Billing and clinical teams must implement prior authorization requirements for all Epoetin Alfa claims (J7171, J7173, J7174) across Medicare Part B, Medicare Part D, and Medicaid (SC/VA) members. Update billing system to enforce: (1) Step-therapy protocol requiring documented inadequate response to preferred products (Retacrit/Procrit for Part B; Retacrit for Part D) for at least 2 consecutive months before approving non-preferred products; (2) Mandatory clinical documentation collection including hemoglobin/hematocrit levels (within 4 weeks), iron studies (transferrin saturation ≥20% OR ferritin ≥100 ng/mL within 4 months), and exclusion of alternative anemia causes (iron/B12/folate deficiency, hemolysis, bleeding) BEFORE claim submission. Providers must document specific anemia indication (CKD, HIV/AZT, chemotherapy, pre-surgical, MDS, hepatitis C, or RA treatment) on all requests. For continuation therapy, update renewal criteria to require current hemoglobin documentation and iron store verification within 4 months. Train all billing staff, coders, and provider liaisons on new documentation requirements. Failure to obtain prior authorization or provide required documentation will result in claim denials.